Maximilian Merz: Splenomegaly, CAR T-Cell Therapy, Relapsed Myeloma
Maximilian Merz, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn about a paper he co-authored with his colleagues published in Transplantation and Cellular Therapy of ASTCT:
“Finally out in Transplantation and Cellular Therapy of ASTCT
Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma.
Major shoutout to co–first authors Thomas Wiemers and Maximilian Ferle — the Dynamic Data Duo — for driving the predictive modeling and analytics that made this work possible.
Clear massages!
Splenomegaly significantly associated with:
- severe and prolonged thrombocytopenia
- higher metabolic tumor volumes from PET/CT
- elevated sBCMA levels
- independent prognostic factor for PFS and OS
Yet another great collaboration between hematologists and radiologists from the Leipzig University and Universitätsklinikum Carl Gustav Carus Dresden.”
Title: Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma
Authors: Thomas Wiemers, Maximilian Ferle, Jonas Ader, Veronika Sotikova, David Fandrei, Nora Grieb, Luise Fischer, Patrick Born, Heike Weidner, Song Yau Wang, Madlen Jentzsch, Georg-Nikolaus Franke, Carmen Herling, Klaus Metzeler, Marco Herling, Simone Heyn, Timm Denecke, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Thomas Neumuth, Hans-Jonas Meyer, Maximilian Merz
Read the Full Article on Transplantation and Cellular Therapy of ASTCT
More posts featuring Maximilian Merz.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023